Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity.

Publication Type:

Journal Article


Gut, Volume 63, Issue 11, p.1769-81 (2014)


2014, Center-Authored Paper, Clinical Research Division, Comp Med Small Animal, Comparative Medicine Core Facility, Experimental Histopathology Core Facility, Flow Cytometry Core Facility, March 2014, Public Health Sciences Division


Pancreatic ductal adenocarcinoma (PDA) is characterised by a robust desmoplasia, including the notable accumulation of immunosuppressive cells that shield neoplastic cells from immune detection. Immune evasion may be further enhanced if the malignant cells fail to express high levels of antigens that are sufficiently immunogenic to engender an effector T cell response.